Korea Investment CORP Acquires New Stake in United Therapeutics Corporation $UTHR

Posted by Brenda Bartman on Aug 25th, 2026

Korea Investment CORP bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 17,800 shares of the biotechnology company’s stock, valued at approximately $9,645,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $2,868,735,000. Avoro Capital Advisors LLC increased its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC raised its stake in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the period. Finally, Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 434,075 shares of company stock valued at $233,942,595 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada reduced their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $646.00.

Read Our Latest Analysis on United Therapeutics

United Therapeutics Stock Down 0.0%

NASDAQ:UTHR opened at $512.88 on Tuesday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The stock’s 50-day simple moving average is $532.35 and its 200 day simple moving average is $538.04. The firm has a market capitalization of $22.00 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $6.41 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.